|

Immunotherapy （Envafolimab） Clinical Trials

1 actively recruiting trial

Also known as: Envafolimab

Pipeline

Phase 2: 1

Top Sponsors

  • Shanghai Chest Hospital1

Indications

  • Lung Cancer, Small Cell1
  • Lung Cancer1
  • Cancer1

Other1 trial

Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.